September 7, 2025 • 3 mins
Togo this week marked a critical milestone in the global fight against malaria, becoming the latest country to introduce the R21/Matrix-M malaria vaccine into its national immunization program. According to the Ecofin Agency, the campaign began on September 1, 2025, and targets approximately 269,000 children across all 39 health districts in the country. The focus is on children under five, who account for the majority of malaria cases and deaths locally. The Health and Public Hygiene Minister, Tchin Darré, emphasized that the program aims to liberate communities from the grip of malaria by 2030, enabling them to contribute effectively to the country's development. This widespread initiative is possible thanks to a partnership involving the Togolese government, WHO, UNICEF, Gavi, and other partners.
The R21/Matrix-M vaccine campaign in Togo represents a significant step forward in malaria prevention on the African continent, as Togo joins countries like Ghana, Benin, and Nigeria in vaccine adoption. Togofirst.com reports that the vaccine, delivered in a four-dose schedule between the ages of 5 and 15 months, is expected to reach annual coverage rates of 80% for the first dose and 70% for the completion dose. Health officials aim to cut malaria-related child morbidity and mortality by 65% by 2030. For Togo, where the disease accounts for 40% of outpatient consultations and 25% of hospital admissions, especially affecting children, the campaign represents an essential public health response.
However, the challenge extends beyond vaccine rollout. Health authorities underscore the importance of community engagement, tackling misinformation, and securing adequate resources to ensure sustainable success. The government will need to persuade parents to participate, dispel rumors about vaccination, and maintain logistical and financial support over the years ahead.
Meanwhile, innovation in malaria vaccine development continues to accelerate globally. On September 4, 2025, Acuitas Therapeutics announced significant progress in developing an mRNA-based vaccine against Plasmodium vivax malaria, a different but highly significant strain of the parasite. According to the company, their clinical studies have demonstrated strong protection, adding a promising new tool to the fight against malaria.
Yet, scientific challenges remain, especially in regions where other parasitic diseases, such as helminth infections, are common. Researchers like Dr. Rajagopal Murugan, who has recently received an ERC starting grant as highlighted by Leiden University Medical Center, are investigating how these co-infections may undermine the effectiveness of malaria vaccines. Murugan’s research aims to identify where the immune response breaks down and to find solutions tailored for populations most at risk.
All of these developments occur against a backdrop of a complex threat. Malaria remains endemic across large swathes of sub-Saharan Africa, with transmission and disease burden surging during rainy seasons. In Togo alone, official statistics from the Ministry of Health show that in 2022, children under five represented 64% of confirmed cases and 65% of hospital deaths linked to malaria.
In light of the recent breakthroughs and ongoing challenges, global health agencies and researchers are focused both on enlarging vaccine access and on refining scientific approaches to ensure malaria elimination is achievable for every community.
This content was created in partnership and with the help of Artificial Intelligence AI
The R21/Matrix-M vaccine campaign in Togo represents a significant step forward in malaria prevention on the African continent, as Togo joins countries like Ghana, Benin, and Nigeria in vaccine adoption. Togofirst.com reports that the vaccine, delivered in a four-dose schedule between the ages of 5 and 15 months, is expected to reach annual coverage rates of 80% for the first dose and 70% for the completion dose. Health officials aim to cut malaria-related child morbidity and mortality by 65% by 2030. For Togo, where the disease accounts for 40% of outpatient consultations and 25% of hospital admissions, especially affecting children, the campaign represents an essential public health response.
However, the challenge extends beyond vaccine rollout. Health authorities underscore the importance of community engagement, tackling misinformation, and securing adequate resources to ensure sustainable success. The government will need to persuade parents to participate, dispel rumors about vaccination, and maintain logistical and financial support over the years ahead.
Meanwhile, innovation in malaria vaccine development continues to accelerate globally. On September 4, 2025, Acuitas Therapeutics announced significant progress in developing an mRNA-based vaccine against Plasmodium vivax malaria, a different but highly significant strain of the parasite. According to the company, their clinical studies have demonstrated strong protection, adding a promising new tool to the fight against malaria.
Yet, scientific challenges remain, especially in regions where other parasitic diseases, such as helminth infections, are common. Researchers like Dr. Rajagopal Murugan, who has recently received an ERC starting grant as highlighted by Leiden University Medical Center, are investigating how these co-infections may undermine the effectiveness of malaria vaccines. Murugan’s research aims to identify where the immune response breaks down and to find solutions tailored for populations most at risk.
All of these developments occur against a backdrop of a complex threat. Malaria remains endemic across large swathes of sub-Saharan Africa, with transmission and disease burden surging during rainy seasons. In Togo alone, official statistics from the Ministry of Health show that in 2022, children under five represented 64% of confirmed cases and 65% of hospital deaths linked to malaria.
In light of the recent breakthroughs and ongoing challenges, global health agencies and researchers are focused both on enlarging vaccine access and on refining scientific approaches to ensure malaria elimination is achievable for every community.
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Togo this week marked a critical milestone in the global
fight against malaria, becoming the latest country to introduce the
R twenty one Matrix M malaria vaccine into its national
immunization program. According to the Ecofin agency, the campaign began
on September one, twenty twenty five, and targets approximately two
hundred sixty nine thousand children across all thirty nine health
(00:23):
districts in the country. The focus is on children under five,
who account for the majority of malaria cases and deaths locally.
The Health and Public Hygiene Minister Chindare emphasized that the
program aims to liberate communities from the grip of malaria
by twenty thirty, enabling them to contribute effectively to the
country's development. This widespread initiative is possible thanks to a
(00:47):
partnership involving the Togolese government, WHO, UNICEF, GAVI and other partners.
The R twenty one Matrix M vaccine campaign in Togo
represents a significant step forward in malaria prov on the
African continent, as Togo joins countries like Ghana, Benin and
Nigeria in vaccine adoption. Togo First dot Com reports that
(01:09):
the vaccine delivered in a four dose schedule between the
ages of five and fifteen months, is expected to reach
annual coverage rates of eighty percent for the first dose
and seventy percent for the completion dose. Health officials aim
to cut malaria related child morbidity and mortality by sixty
five percent by twenty thirty For Togo, where the disease
(01:30):
accounts for forty percent of outpatient consultations and twenty five
percent of hospital admissions, especially affecting children, the campaign represents
an essential public health response. However, the challenge extends beyond
vaccine rollout. Health authorities underscore the importance of community engagement,
tackling misinformation, and securing adequate resources. To ensure sustainable success.
(01:55):
The government will need to persuade parents to participate, dispel
rumors about vaccination, and maintain logistical and financial support over
the years ahead. Meanwhile, innovation in malaria vaccine development continues
to accelerate globally. On September fourth, twenty twenty five, Acutis
Therapeutics announce significant progress in developing an mRNA based vaccine
(02:17):
against Plasmodium vivax malaria, a different but highly significant strain
of the parasite. According to the company, their clinical studies
have demonstrated strong protection, adding a promising new tool to
the fight against malaria. Yet scientific challenges remain, especially in
regions where other parasitic diseases such as helminth infections are common.
(02:40):
Researchers like doctor Rodigopol Marugan, who has recently received an
erc starting grant, as highlighted by Leiden University Medical Center,
are investigating how these coinfections may undermine the effectiveness of
malaria vaccines. Marugan's research aims to identify where the immune
response breaks down in too fine solutions tailored for populations
(03:02):
most at risk. All of these developments occur against a
backdrop of a complex threat. Malaria remains endemic across large
swathes of Sub Saharan Africa, with transmission and disease burdens
surging during rainy seasons. In Togo alone, official statistics from
the Ministry of Health show that in twenty twenty two,
children under five represented sixty four percent of confirmed cases
(03:26):
and sixty five percent of hospital deaths linked to malaria.
In light of the recent breakthroughs and ongoing challenges, global
health agencies and Researchers are focused both on enlarging vaccine
access and on refining scientific approaches to ensure malaria elimination
is achievable for every community.
Togo this week marked a critical milestone in the global
fight against malaria, becoming the latest country to introduce the
R twenty one Matrix M malaria vaccine into its national
immunization program. According to the Ecofin agency, the campaign began
on September one, twenty twenty five, and targets approximately two
hundred sixty nine thousand children across all thirty nine health
(00:23):
districts in the country. The focus is on children under five,
who account for the majority of malaria cases and deaths locally.
The Health and Public Hygiene Minister Chindare emphasized that the
program aims to liberate communities from the grip of malaria
by twenty thirty, enabling them to contribute effectively to the
country's development. This widespread initiative is possible thanks to a
(00:47):
partnership involving the Togolese government, WHO, UNICEF, GAVI and other partners.
The R twenty one Matrix M vaccine campaign in Togo
represents a significant step forward in malaria prov on the
African continent, as Togo joins countries like Ghana, Benin and
Nigeria in vaccine adoption. Togo First dot Com reports that
(01:09):
the vaccine delivered in a four dose schedule between the
ages of five and fifteen months, is expected to reach
annual coverage rates of eighty percent for the first dose
and seventy percent for the completion dose. Health officials aim
to cut malaria related child morbidity and mortality by sixty
five percent by twenty thirty For Togo, where the disease
(01:30):
accounts for forty percent of outpatient consultations and twenty five
percent of hospital admissions, especially affecting children, the campaign represents
an essential public health response. However, the challenge extends beyond
vaccine rollout. Health authorities underscore the importance of community engagement,
tackling misinformation, and securing adequate resources. To ensure sustainable success.
(01:55):
The government will need to persuade parents to participate, dispel
rumors about vaccination, and maintain logistical and financial support over
the years ahead. Meanwhile, innovation in malaria vaccine development continues
to accelerate globally. On September fourth, twenty twenty five, Acutis
Therapeutics announce significant progress in developing an mRNA based vaccine
(02:17):
against Plasmodium vivax malaria, a different but highly significant strain
of the parasite. According to the company, their clinical studies
have demonstrated strong protection, adding a promising new tool to
the fight against malaria. Yet scientific challenges remain, especially in
regions where other parasitic diseases such as helminth infections are common.
(02:40):
Researchers like doctor Rodigopol Marugan, who has recently received an
erc starting grant, as highlighted by Leiden University Medical Center,
are investigating how these coinfections may undermine the effectiveness of
malaria vaccines. Marugan's research aims to identify where the immune
response breaks down in too fine solutions tailored for populations
(03:02):
most at risk. All of these developments occur against a
backdrop of a complex threat. Malaria remains endemic across large
swathes of Sub Saharan Africa, with transmission and disease burdens
surging during rainy seasons. In Togo alone, official statistics from
the Ministry of Health show that in twenty twenty two,
children under five represented sixty four percent of confirmed cases
(03:26):
and sixty five percent of hospital deaths linked to malaria.
In light of the recent breakthroughs and ongoing challenges, global
health agencies and Researchers are focused both on enlarging vaccine
access and on refining scientific approaches to ensure malaria elimination
is achievable for every community.
Popular Podcasts
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.